{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:08:38Z","timestamp":1753877318308,"version":"3.41.2"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To describe reasons for initiation and evolution under isavuconazole (ISZ), a 2-year prospective and observational study was performed. Anonymized data collected during the first 3 months of treatment were indications of treatment, efficacy, overall survival (OS), evolution of toxicity markers, and ISZ trough levels. Fifty-one (26 invasive aspergillosis, 16 prophylaxis, and 9 mucormycosis) patients started on isavuconazole. Isavuconazole was initiated upfront in 12\/51 cases, especially to avoid toxicities from other antifungals. As second-line therapy (39\/51 patients), isavuconazole was mostly initiated after toxicities of the previous treatments (66.7%; 26\/39 cases). An improvement in toxicity markers was reported in most patients. However, five patients experienced adverse events. The mean ISZ trough levels measured from 179 samples collected in 37 patients was 3.33 \u00b1 1.64\u00a0mg\/l. The mean ISZ through levels was significantly lower (P\u00a0=\u00a0.003) in alloHSCT recipients (3.10 \u00b1 1.45\u00a0mg\/l) than in other patients (3.76 \u00b1 1.88\u00a0mg\/l) but still within the expected range of efficacy. After 12 weeks, the OS was 69.2% (n\u00a0=\u00a018\/26) in the invasive aspergillosis intention-to-treat (ITT) group and 44.4% (n\u00a0=\u00a04\/9) in the mucormycosis ITT group. After 2 years, the OS was respectively 46.2% (n\u00a0=\u00a012\/26) and 33.3% (n\u00a0=\u00a03\/9) in these two groups.<\/jats:p>","DOI":"10.1093\/mmy\/myad033","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:36:50Z","timestamp":1679704610000},"source":"Crossref","is-referenced-by-count":5,"title":["Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-2485","authenticated-orcid":false,"given":"R\u00e9mi","family":"Pieragostini","sequence":"first","affiliation":[{"name":"Service de Pharmacie , H\u00f4pital Avicenne, 125 rue de Stalingrad, 93000 Bobigny , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali\u00e9nor","family":"Xhaard","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Greffe , H\u00f4pital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Sauvageon","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie , H\u00f4pital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Service de Pharmacie , H\u00f4pital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Touratier","sequence":"additional","affiliation":[{"name":"Service de Pharmacie , H\u00f4pital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Denis","sequence":"additional","affiliation":[{"name":"Service de Maladies infectieuses et tropicales , H\u00f4pital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis."},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis."},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12569","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: a review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis."},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"year":"2019","author":"U.S. Department of Health and Human Services NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","key":"2023040508045387100_"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"Dipippo","year":"2019","journal-title":"Mycoses"},{"key":"2023040508045387100_","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad033\/49629567\/myad033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/4\/myad033\/49762019\/myad033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/4\/myad033\/49762019\/myad033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T11:40:36Z","timestamp":1702122036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad033\/7085764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad033","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"type":"print","value":"1369-3786"},{"type":"electronic","value":"1460-2709"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,3,24]]},"article-number":"myad033"}}